Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

摘要: Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, introduction of chemotherapy led to a dramatic improvement in prognosis for patients with localized osteosarcoma; long-term survival rates less than 20% improved 65% 70% after advent multiagent regimens. Controversy concerning ideal combination agents ensued throughout last quarter 20th century because conflicting often nonrandomized data. large cooperative group studies international collaboration have demonstrated effective regimens include high-dose methotrexate, doxorubicin, cisplatin (MAP). The biologic such as muramyl tripeptide use additional cytotoxic ifosfamide not definitively osteosarcoma. Collaborative efforts increase understanding biology osteosarcoma preclinical models test novel will be critical identify path toward improving outcomes patients. Once promising are identified, an infrastructure exists clinical trials. Herein, biologic, preclinical, trial described along future collaborative strategies improve who develop this challenging tumor.